To beat J&J, Pfizer attempts a New Merger…Guess who’s the Target this Time?!

29/10/2015 - 2 minutes

Mergers & acquisitions (or M&A in short)  have ruled the world of Pharma for a while and the company which seems to be the most hungry this year is Pfizer! After it failed to buy AstraZeneca in May 2015 for $118Bn (woah!!), the company is still trying to become the biggest Pharma company worldwide…

This time, the target is Allergan. This company based in Dublin (Ireland), has already been acquired by Actavis early last year (March 2014). But this does not stop Pfizer.

Beside the value of the resulting merger (up to $300M according to Fortune), what are the further advantages of this merger for Pfizer?

  • A bigger portfolio in biotechnologies and several relatively unexplored therapeutic areas (e.g., the Gastrointestinal and Central Nervous Systems)
  • Products from Anesthetic & Corrective fields such as Botox, where Allergan is one of the leaders in the field. And from my experience at Galderma, I can tell you that A&C might grow a lot in the following years…

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member